5 results
- To assess the pharmacokinetic profile of cysteamine base after single dose administration of the new sustained-release cysteamine bitartrate (PO-001) to healthy volunteers, in comparison with Cystagon® and Procysbi®.- To collect safety/…
Primary Objectives:Use 89Zr-Trastuzumab to characterise the in vivo biodistribution using PET imaging in the primary tumour and distant metastases.Comparie the uptake in patients with Her2/neu positive breast cancer to patients with HER2/neu…
The primary objective (on lesion-based analysis) is to show that pre-treatment 89Zr-trastuzumab PET/CT is able to select lesions not responding morphologically from treatment with T-DM1 (applying RECIST 1.0 criteria)Secondary Objectives and…
Comparison of steady-state cysteamine-trough WBC cystine levels between Cystagon® and RP103 over 3 months for each treatment period.
Primary objectives • To characterize the histamine dose response on pruritus• To profile the response to intradermal histamine by:o Clinical measureso Biophysical measureso Imagingo Molecular and cellular responsesSecondary objective • Comparison to…